

Index

a

achiral thiol-coated CdTe 7
 aflatoxin B1 (AFB1) 180
 aggregation-induced emission (AIE) 216
 Ag shell of Au@Ag NPs 45
 aldol reaction 254, 255, 256
 allosteric effect 117, 120
 alpha-fetoprotein (AFP) 156, 159
 amino acids 11, 28, 30, 31, 35, 38, 40, 41, 59, 62, 129, 139, 150, 155, 184, 186, 187, 189, 190, 237, 241–244, 246–248, 250, 254–257, 259–262, 275, 278, 280
 4-(4-(aminomethyl)-1,3,2-dioxaborolan-2-yl)benzenethiol (AMDBT) 273
 anti-TROP monoclonal antibodies (mAb) 160
 asymmetric transfer hydrogenation (ATH) reaction 270
 atomic packing 4, 6, 257
 Au@Ag@Au NP-UCNP heterodimers 181, 182
 AuCuAu NRs 203
 Au/(DNA-Ag) core-shell NPs 44–46
 Au@gap@AgAu NPs 178
 Au-gap-Ag NPs 233, 236
 Au NP-Ag NP dimers 157, 158
 Au NP helices 103, 104
 Au NP heterotrimers 180
 Au NPs metallic core 42
 Au NR dimer@UCNP structures 225, 226
 Au NR helices 103, 104
 Au NR SBS dimers 82, 83, 85
 Au₃₈(SCH₂CH₂Ph)₂₄ NP 5
 Au-thiolate ligand 5

azobenzene-hosted nanostructures 82

b

base complementary pairing 153
 beta-2-microglobulin (beta 2 MG) 273
 bimetallic NPs 178, 189
 binaphthyl compound (BINAP) 10, 60, 61, 81
 biocatalysis
 biological applications 269–282
 biological macromolecule 261–265
 drugs 249–257
 encoded chiral complex nanomaterials system 264, 266–269
 peptide 257–261
 biological macromolecule 11, 70, 173, 261–265
 biological transparency windows 80
 biomarkers bioanalysis 156–164
 biomolecules 11, 12, 28, 38, 40, 89, 149, 150, 162, 184, 193, 244, 261, 281
 bisphenol A (BPA) 175–177
 Brunauer-Emmett-Teller (BET) surface 116

c

cadmium telluride (CdTe) NPs 7, 11, 29, 33, 135, 139, 262, 263, 264, 266, 268, 269
 CdSe nanorods (NRs) 32, 35
 CdSe/ZnS nanocrystals 17
 CdS QDs 181–183
 cell cycle progresses 169
 cell death (Ferroptosis) 200, 209
 cell models 280

- Ce NPs 242, 243
- Ce NPs oxidase-like activity 242
- ceramic nanohelices 69–70
- ceramic NPs 257
- chemodynamic therapy 206
- chiral Au NP heterodimers 152, 153, 156, 157, 159, 175, 176
- chiral carbon dots (CDs) 29, 182, 183, 190, 274
- chirality
 - characterization methods
 - computational studies 14–17
 - computer-modeling study 17–20
 - optical spectra 12–14
 - definition 1
 - materials
 - biological nano- and mesoscale compounds 11
 - hierarchical chirality 11–12
 - inorganic and organic molecular 10–11
 - molecules 2
 - nanoparticles 2
 - origin of nanomaterials
 - geometries 2–6
 - structural origins 6–10
- chiral mesoporous silica layer 41
- chiral nanoassemblies
 - core-satellite nanoassembly 113–129
 - helices 100–111
 - nanochains 111–113
 - nanoparticle dimers 85–90
 - nanoplatelets and chiral films 129–134
 - supraparticles (SPs) 134–139
 - tetramer assemblies 90–100
 - twisted nanorod pairs 80–85
- chiral nanocrystals
 - chiral metal nanostructure
 - metal nanohelices 50–54
 - metal nanoparticles/nanorods 41–50
 - metal nanorings and superstructures 54–59
 - metallic compound nanoparticles
 - ceramic nanohelices 69–70
 - oxide nanoparticles 59–64
 - sulfide/selenide nanoparticles 64–68
 - semiconductor helicoids 38–39
 - semiconductor nanoparticles 29–38
 - synthetic methods 28
- chiral nanomaterials
 - biocatalysis 241–249
 - multimodal therapy methods 220–234
 - photochemical effects 233, 235–237
 - photodynamic therapy (PDT) 209–220
 - photothermal therapy 199–209
- chiral nanomaterials based
 - enantioselectivity 241–249
- chiral nanostructures
 - analysis strategy 149–150
 - biomarkers bioanalysis 156–164
 - DNA detection 150–156
 - enzymes bioanalysis 164–170
 - metal ions bioanalysis 170–175
 - recognition 184–193
 - small molecules detection 175–184
- chiral plasmonic NPs 40, 233, 236, 237, 273
- chiral recognition 27, 184–193, 244, 246
- chlorin e6 (Ce6) 127, 128, 209, 210, 211, 225, 226
- circular dichroism (CD) 6, 8, 9, 12–19, 27, 28, 30–38, 41–53, 55, 57, 60–62, 65, 66, 68, 80–104, 106–114, 116–119, 121, 122, 124–127, 129, 131, 133, 135, 137, 138, 150, 152, 153, 155, 156, 158, 160, 161–165, 167, 169, 170, 171, 173, 175, 177, 178, 180–182, 184, 186, 187, 189, 190–192, 203, 221, 233, 235, 236, 252, 253, 257, 259, 260, 262, 263, 264, 265, 268–271, 273–279
- circularly polarized light (CPL) 13, 49, 107, 108, 109, 110, 111, 117, 127, 174, 175, 201, 203, 221, 235, 236, 237, 262
- circularly polarized luminescence (CPLm) 27, 108, 109
- circular polarized light (CPL) 13, 49, 107, 108, 109, 110, 111, 117, 127, 174, 175, 201, 203, 221, 235, 236, 237, 262
- circulating tumor cells (CTCs) 156
- classical hot-injection technique 35
- cogel formation 108

- complementary ssDNAs 126
 copolymer polystyrene-block-poly (acrylic acid) (PS-b-PAA) 127
 core-satellite nanoassembly 80, 113–129
 core-satellite nanostructures 119, 122, 127, 164
 Cotton Effect 43, 50, 53, 60, 65, 101, 131, 189, 252
 Coulomb dipole-dipole interactions 30
 covalent organic frameworks (COFs) material 246
 crystalline porous materials 246
 Cu_{2-x}Se-Au coupling 207
 Cu_{2-x}Se-Au Janus NPs 207, 208
 Cys-decorated CdTe NPs 33
 cystine enantiomers 187, 188
- d**
 D- and L-penicillamine (Pen) 273, 274
 D-Cu_xCo_yS NPs 273
 Density Functional Theory (DFT) 6, 15–17, 41
 deoxyribonuclease I (DNase I) 42, 165, 168
 deoxyribonucleotide sequences 164
 D-gelators 108
 D-GSH 32, 57, 96, 275, 277, 280
 diastereomers 2, 28
 diffuse-reflectance circular dichroism (DRCD) 53, 54
 3,4-dihydroxyphenylalanine (DOPA) 242–247, 260
 1,3-diphenylisobenzofuran (DPBF) 229
 DL-dithiothreitol (DTT) 82
 D/L-12-hydroxystearic acid (HSA) 52, 264
 D/L-penicillamine (D/L-Pen) 4, 41, 122, 123, 125, 189, 191
 D/L-penicillamine ligands 4
 DNA-bound Au cores (Au NPs-DNA) 44
 DNA detection 100, 150–156
 DNA driven chiral nanomaterials 165
 DNA endonuclease 164
 DNA functionalization 79
 DNA methyltransferase 164–168
 DNA origami 81, 82, 101–103, 107
 DNA-origami-organized NPs 101
 DNA origami templates 81, 82, 103
 DNzyme 127, 173, 175
- double hydrophilic block copolymers (DHBC) 69
 double-layer DNA origami template 82
 D-penicillamine 31, 131, 259
 D-tartaric acid functionalized Au NPs (D-Au NPs) 187
 D-tyrosinol 248
 dual-mode optical biosensor 170, 181
 dynamic light scattering (DLS) 260
 dynamic NP dimer 88
- e**
 effective core potential (ECP) 15–17, 19
 electrostatic repulsion 80, 89, 101, 129, 131, 266, 268
 enantiomeric ligand functionalized silver NPs 41
 enantiomers 1, 2, 5–7, 9, 12, 13, 28, 41, 47, 53, 56–58, 61, 80, 93, 100, 101, 113, 137, 184, 186–191, 242–248, 259–261, 270
 enzyme bioanalysis 164–170
 epidermal growth factor receptor 2 (HER2) 156, 162, 163
 epithelial cell-adhesion molecule (EpcAM) 162, 163
 expanded mesoporous silica (EMSN) 162, 244, 245
- f**
 Fenton reaction 213
 ferroptosis 208, 209
 Fourier transform (FT) IR spectroscopy 242, 244, 250, 254, 257, 258, 266
- g**
 gelators N-(9-fluorenylmethoxycarbonyl)-protected glutamic acid (Fmoc-Glu) 108
 generalized gradient approximation (GGA) 19
 gold nanorods (Au NRs) 11, 41, 50, 51, 80–83, 85, 89, 100, 103, 104, 107, 111–114, 119, 120–123, 126, 127, 129, 135, 150–152, 154, 155, 159, 160, 165, 167, 170–172, 174, 175, 186, 187, 200–204, 218, 220, 222, 223, 225, 226, 229, 232, 274
 gold (III) tetrachloride acid 40

- gold-upconversion nanoparticle
(Au-UCNP) pyramids 92, 94
- gold yolk-shell nanoparticles 89
- Gram-positive bacteria (*S. aureus*)
249
- graphene quantum dots (GQDs)
12, 29
- h**
- Hausdorff chirality measure (HCM) 7,
19
- HBV core antigen (HBcAg) 278
- Hepatitis B virus (HBV) infection 278,
279
- heterochains 111, 112, 152
- high-resolution transmission electron
microscopy (HRTEM) 33, 34, 36,
37, 46, 51, 57, 59, 63, 66, 91, 116,
126, 252, 253
- hot-spot CD amplification 86
- hydrogels 107–109, 111
- 8-hydroxy-2'-deoxyguanosine (8-OHdG)
156–158
- hypoxia environment 212
- i**
- inner filter effect (IFE) 181
- intensive plasmonic coupling 189, 201,
225
- intensive plasmonic properties of NPs
201
- iron dependent lipid peroxidation 209
- iron 5,10,15,20-tetrakis(40-
tetraphenylamino) porphyrin unit
(Fe-ATPP) 246
- N*-isobutryl-cysteine 4
- k**
- Kohn-Sham orbitals 16, 17
- l**
- L-aspartic acid (L-Asp) 62, 190, 258
- L-cysteine methylester 4
- left circular polarized (LCP) light
illumination 129
- Lewis acid-surfactant combined catalysts
(LASC)-SWNT 255
- Lewis basicity 250
- L-gelators 108
- L-GS-bimane 42, 43
- linear amino acids 254, 255
- local density approximation (LDA) 19
- localized surface plasmon resonance
(LSPR) effect 65, 121, 199, 206,
207, 232
- L-penicillamine 4, 31, 40, 41, 122, 131,
189, 263, 273, 274
- LPF@5 hybrid complex 250
- L-proline@Fe₃O₄ nanoparticle
250, 251
- L-tartaric acid modified Au NPs
(L-Au NPs) 187
- L-tyrosinol 248, 249, 252
- luminescence resonance energy transfer
(LRET) 92, 164, 170
- m**
- macromolecules 11, 70, 173, 175,
261–264
- magnetic nanoparticles 249, 250
- 2-mercaptobenzoimidazole-5-carboxylic
acid (MBIA) 180
- 16-mercaptohexadecanoic acid
(16-MHDA) 160
- mesoporous silica nanoparticles (MSN)
270, 271
- metal-semiconductor hybrid
nanoassemblies 89
- metal ions bioanalysis 170
- metal organic frameworks (MOFs) 10,
115, 201, 216, 246
- metal-semiconductor composite
nanostructures 232
- metal-to-ligand charge transfer (MLCT)
transitions 12
- Michaelis-Menten reaction 252
- microcystins 175, 177
- microRNA (miRNA) 82, 85, 92, 94,
118, 119, 150, 156, 162, 163,
164, 170
- MnO₂@Au NPs structures 207, 208
- MoO_x NPs 225, 229, 230
- multimodal therapy methods
220–233
- mycotoxins 114, 178, 180, 181
- n**
- nanochains 80, 111–114

- nanoclusters 6, 7, 8, 29, 40, 42, 44, 122, 280
- nanographene oxides (NGO)-capsulate
AIE photosensitizers 216
- nanohelical chirality 111
- nanozymes 33, 209, 246, 247, 253, 261, 262
- natural enzymes 241, 244, 246, 247, 252, 261, 280
- near-infrared (NIR) laser induced
phototherapy 225
- neural stem cells (NSCs) 117, 118, 236
- NGP-TPERed 216, 217, 218
- nicotinamide adenine dinucleotide
phosphate (NADPH) 268–270
- β -nitroalcohol 250
- non-racemate 2, 3
- 1:1 NP-CytC dispersion 268
- NPs plasmonic frequency 87
- o**
- ochratoxin A (OTA) 113, 178–180
- optical rotation dispersion (OR or ORD)
spectra 12
- ORD spectrum 12–13
- organic and inorganic helicoids 101
- organogelators 52
- p**
- peroxidase-like activity 244, 252, 253, 280
- photochemical effects 233–237
- photodynamic therapy (PDT) 127, 181, 209–220, 209–223, 225–229, 231, 232
- photosensitizers (PSs) synthesis 216
- photothermal conversion efficiency 200, 201, 204, 206, 207, 209, 212, 221, 223, 227, 229, 231, 232, 233
- photothermal therapy 199, 202, 203, 205, 208
- plasmon hybridization terminology 81
- plasmonic effects 33, 80
- plasmonic enhancement effects 6
- plasmonic metal NP-semiconductor
229, 231
- plasmonic metal-semiconductor
heterostructures 206
- plasmonic molecules 131
- plasmonic nanomaterials 220
- plasmonic NPs 6, 8, 9, 40, 180, 190, 199, 221, 225, 229, 233, 237
- plasmonic NR dimers 82, 83
- plasmonic walking device 82
- plasmon-induced resonant absorption
43
- platelet membrane (PM) 138, 277
- poly(cyclopentadithiophene-alt-
benzothiadiazole) 212, 213
- poly(styrene-*b*-acrylic acid) (PS-PAA)
82, 85
- polycationic nonapeptide 263
- polymerase chain reaction (PCR)
approach 100
- polymyxin B 181, 183
- polyphosphoester-based nanocarrier
(NP-PPE) 210
- polyvinylpyrrolidone (PVP) 47, 61, 114
- powder X-ray diffraction (XRD) 242
- Pro-GnO chiral catalysts 253, 254
- prostate specific antigen (PSA) 156, 158–160
- protein biosensing 104
- protoporphyrin IX (PpIX) 213
- PS-free nanostructures 217
- q**
- quantum dots (QDs) 12, 18, 25, 29, 31, 33, 35, 38, 65, 88, 89, 93, 107–109, 111, 118, 119, 135, 139, 181–184, 219, 252, 253, 262–265, 270
- r**
- racemic mixtures 2, 35, 50
- reactive oxygen species (ROS) 68, 117, 175, 200, 207, 209, 210, 212, 213, 217, 219–221, 223, 226, 227, 229–234, 262, 263, 265, 270–275, 277–281
- RT-PCR method 150
- s**
- (S)- β -nitroalcohol 250
- (S)-carbonyl reductase II-glucose
dehydrogenase on nanoparticles
(SCRII-GDHnano) 266

- SELEX (Systematic Evolution of Ligands by Exponential Enrichment) 213
- self-limiting method 134, 135
- semiconducting polymer NP core 212
- semiconductor nanorods (SNR) 30, 35, 37, 38, 122, 262
- side-by-side (SBS) dimers 80, 82, 83, 85
- sodium borohydride (NaBH_4) 40, 189
- sodium citrate 40, 80
- sphalerite (ZB) 32
- stereoselectivity 242–244, 246, 255
- sulfamethazine (SMZ) 181, 182
- sulfide/selenide nanoparticles 64–68
- supraparticles (SPs) 11, 27, 134–139, 259, 266, 268
- surface-enhanced Raman scattering-chiral anisotropy (SERS-ChA) effect 58
- surface ligands 2–6, 8, 11, 12, 28, 29, 40, 41, 44, 61, 130, 271
- synthetic organic chemistry 255
- t**
- targeted bioorthogonal catalysis 269
- tetramer assemblies 79, 80, 90–100
- three-dimensional (3D) distortion 29
- TMD quantum dots (QDs) 252
- transition metal sulfides 227
- transmission electron microscopy (TEM) 31–34, 37, 39, 45, 47–49, 51, 52, 55–58, 61–68, 70, 80, 81, 87, 90, 91, 93–97, 102, 103, 105, 109, 111–116, 118–121, 124–126, 128, 129, 131, 133, 136, 138, 200, 242–245, 249, 250, 253, 258, 260, 265, 268, 270, 271
- triphenylphosphine (TPP)-grafted dextran (Dex-TPP) 213
- triphenylphosphonium (TPP) 274
- tropomyosin (TROP) 160, 161
- twisted nanorod pairs 80
- two dimensional (2D) transition metal dichalcogenides (TMDs) 250
- type 2 chirality of NPs 4, 5
- u**
- UCNP@ZIF- NiS_x assemblies 116
- upconversion nanoparticles (UCNPs) 89, 92, 114, 115
- v**
- van der Waals (vdW) forces 101, 104, 131, 149, 248, 268
- vascular endothelial growth factor (VEGF) 156
- venous thromboembolism (VTE) 277
- vibrational circular dichroism (VCD) 8, 12, 15, 18
- w**
- $\text{WO}_{3-x}\text{H}_2\text{O}$ nanocrystals 257–259
- wurtzite (WZ) 32, 35, 136
- x**
- X-ray diffraction (XRD) 15, 57, 66, 67, 130, 132, 242, 244
- y**
- yolk-shell NPs (YSNPs) 95, 229
- yolk-shell NPs (YSNPs) dimers 95
- yolk-shell NPs tetrahedron (UYTe) 95
- yolk-shell NRs (YSNRs) 122, 173, 174
- z**
- zeolitic imidazolate framework-8 (ZIF) 114–116, 209
- zeptomolar DNA detection 153
- zinc selenium (ZnSe) 69, 136
- Zr-based porphyrinic MOF (ZrMOF) NPs 214–216